The ALPCO Glucagon ELISA is for the quantitative determination of glucagon in human EDTA plasma. This assay was developed for ease-of-use and demonstrates superior sensitivity while eliminating cross-reactivity issues present in other commercially-available assays.
ALPCO’s automated turbidimetric solution for calprotectin testing offers enhanced efficiency without compromising clinical sensitivity or specificity. Clinicians can prioritize endoscopic evaluation for the patients that need it most and quickly put IBS patients on the right treatment path.
Join our speaker from Department of Pathology , University of Utah School of Medicine, Dr. Heather Nelson, to discuss how to validate and launch a FDA-approved assay.
ALPCO offers targeted GI solutions suitable for all types of labs. Our offerings range from plate-based to clinical chemistry analyzer-based and automated flash chemiluminescence solutions, all designed to accommodate your lab’s expanding testing needs and capabilities.
In the webinar, Dr. Benjamin Click from the University of Colorado, Department of Gastroenterology, underscores the critical role of non-invasive monitoring methods, particularly fecal calprotectin monitoring, in guiding treatment adjustments and achieving therapeutic goals..
ALPCO’s Active GLP-1 (7-36) amide Chemiluminescence ELISA accurately measures the major biologically active circulating form of GLP-1.1,2 This well-characterized assay provides high analytical sensitivity, a short incubation time, and measures active GLP-1 (7-36) amide in fasted and fed samples.
The STELLUX® Rodent Insulin ELISA provides the flexibility to run both mouse and rat samples on the same plate with minimal to no dilution and a short two hour incubation.
ALPCO’s Insulin Chemiluminescence ELISA detects insulin at levels as low as 20 pg/mL in human serum, plasma, and β-islet tissue culture supernatants, without cross-reactivity to human intact proinsulin, mouse insulin, or rat insulin.
ALPCO's STELLUX® Chemi Active GLP-1 (7-36) Amide ELISA provides accurate quantification and resolves sample size and analytical performance issues.
This infographic distills the essence of the new American Gastroenterological Association (AGA) Clinical Practice Guideline on the Role of Biomarkers in Crohn's Disease (CD). It sheds light on the nuanced recommendations for using biomarkers to monitor and evaluate CD, emphasizing their value in conjunction with clinical symptoms.
